WebMD Health stock could soon resume its bullish trend.

The company is in a good momentum as sales are increasing, +10% last year, and are expected to keep on growing with a 2014 progression of 11%. Moreover, profitability is getting better. Thus, net margin should double in 2014, reaching 6.2% from 2.9% in 2013. Furthermore, Thomson-Reuters analysts have revised upward their revenues and EPS estimations for the two coming years, highlighting the good dynamic of the activity. Hence, 2014 EPS should double 2013 one reaching USD 0.75. Finally, the company stock offers an interesting potential considering the average target price of analyst at USD 53.3.

Following a bullish wave, the stock now shows a slight decline that should lead it toward its USD 38.6 midterm support. At this level, a re-boost of buyers would enable an upturn, with the USD 43 resistance as a target.

Therefore, the USD 38.6 area represents an interesting level for buyers. Once the position taken, the target will then be USD 43. A stop loss will be fixed below the entry point to limit risks.